Texas Takes Control of Ibogaine Research

Texas is moving forward with an independent study into the medical applications of ibogaine, a naturally occurring psychedelic compound. This decision comes after the state was unable to find suitable pharmaceutical partners to collaborate on research.

$50 Million Investment and Initial Setbacks

Last year, Texas allocated $50 million to fund research into ibogaine’s potential for treating conditions like PTSD and other mental health disorders. However, the Texas Health and Human Services Commission announced on Monday that no drug company submitted a proposal that met the state’s requirements for funding and clinical trials.

Legislative Support for Independent Study

Following the lack of pharmaceutical interest, lawmakers announced on Tuesday their intention to conduct the study independently. Lieutenant Governor Dan Patrick and House Speaker Dustin Burrows, who championed the original bill, confirmed their commitment to fully funding the program through the legislature.

What is Ibogaine?

Origins and Potential Benefits

Ibogaine is a psychoactive compound derived from the root of a shrub native to Central and West Africa. Research, including studies from the UC Berkeley Center for the Science of Psychedelics, suggests ibogaine may be effective in treating addiction to opioids, heroin, and cocaine, as well as serving as an antidepressant.

Current Legal Status and Treatment Availability

Currently, ibogaine is classified as a Schedule 1 drug under the United States Controlled Substances Act, indicating a high potential for abuse and no currently accepted medical use. Despite this, ibogaine treatment is available in medically supervised settings in Mexico and New Zealand.

Promising Results with Veterans

In 2024, Stanford Medical collaborated with 30 U.S. special forces veterans who traveled to Mexico for ibogaine treatment for traumatic brain injuries. Veterans received oral ibogaine alongside magnesium to mitigate potential heart complications.

Significant Symptom Reduction

The study revealed a nearly 90% reduction in PTSD, depression, and anxiety symptoms among the veterans following treatment. Formal testing also demonstrated improvements in concentration, memory, and information processing.